~~<i id='F215AF9679'><strike id='F215AF9679'><tt id='F215AF9679'><pre id='F215AF9679'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：fashion 2025-10-08 22:32:02 Page View：6

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Ed Silverman on new gene therapies, biosimilars, coffee, and more

STAT'sEdSilvermanonstageattheSTATBreakthroughSummitin2023.SarahGonzalezforSTATIn2023,STATlaunchedabr

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

5:03PeopleraiseuptheirarmsduringthededicationofaprayerwalloutsideofthehistoricVernonAfricanMethodist

WSS

focus

focus

explore

leisure time

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit